Clinical Trial Update: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study investigating LEE011 (trametinib) in combination with MEK162 in NRAS-mutant melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Nras-mutant Melanoma

Drugs mentioned

• LEE011 (ribociclib)
• MEK162 (binimetinib)

Snippet

Sponsor: Pfizer | Conditions: Locally Advanced or Metastatic NRAS Mutant Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-08-12